Preferred Label : Izastobart;
NCIt synonyms : Anti-C5aR Monoclonal Antibody TJ210; Anti-C5aR1 Monoclonal Antibody TJ210;
NCIt definition : A differentiated human monoclonal antibody targeting the complement component fragment
5a receptor (C5aR1, CD88), with potential immunomodulating and antineoplastic activities.
Upon administration, izastobart specifically targets and binds to the N-terminus of
C5aR1 expressed on subsets of tumor-promoting cells, such as myeloid-derived suppressor
cells (MDSCs), neutrophils and M2 macrophages. This prevents the binding of its ligand
complement factor 5a (C5a) to C5aR1 and prevents the C5aR1-mediated activation, migration
and accumulation of the C5aR1-expressing cells in the tumor microenvironment (TME).
This abrogates the secretion of inflammatory and angiogenic factors by these cells
and restores the activation of T- and natural killer (NK) cells. This results in the
induction of anti-tumor immune responses and inhibits tumor cell proliferation. C5a,
a factor in the complement cascade, is often overexpressed in the TME, where it attracts
and activates C5aR1-expressing tumor-promoting immune cells, and contributes to tumor
immune suppression.;
UNII : 58R5Z64YQ6;
CAS number : 2769937-42-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2769937-42-8
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : MOR 210; MOR-210; MOR044254; WBP2191; TJ210001; TJ 210; TJ-210;
NCI Metathesaurus CUI : CL1642944;
Origin ID : C177110;
UMLS CUI : C5447587;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
